These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26142634)

  • 21. The cellular and physiologic effects of beta blockers in heart failure.
    Sabbah HN
    Clin Cardiol; 1999 Oct; 22 Suppl 5():V16-20. PubMed ID: 10526699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Recent advances and limitations of medical treatment on heart failure].
    Momomura S
    Kyobu Geka; 2007 Jun; 60(6):484-7. PubMed ID: 17564066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifying opportunities to address the congestive heart failure burden: the Improving Cardiovascular Outcomes in Nova Scotia (ICONS) study.
    Howlett JG; Johnstone DE; Sketris I; O'Reilly M; Horne GS; Cox JL;
    Can J Cardiol; 2003 Mar; 19(4):439-44. PubMed ID: 12704493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary prevention of heart failure: an update.
    Dupree CS
    Curr Opin Cardiol; 2010 Sep; 25(5):478-83. PubMed ID: 20679766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. beta-Blocker therapy in heart failure.
    Doughty RN
    Heart Fail Monit; 2000; 1(1):2-7. PubMed ID: 12634875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons.
    Aronow WS
    J Lab Clin Med; 2001 May; 137(5):316-23. PubMed ID: 11329528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What can we learn from Europe?
    Swedberg K
    Heart; 2005 May; 91 Suppl 2(Suppl 2):ii21-3; discussion ii31, ii43-8. PubMed ID: 15831604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure.
    Galbreath AD; Krasuski RA; Smith B; Stajduhar KC; Kwan MD; Ellis R; Freeman GL
    Circulation; 2004 Dec; 110(23):3518-26. PubMed ID: 15531765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ACE inhibitors before or after heart failure?
    Erhardt L
    Eur J Clin Pharmacol; 1996; 49 Suppl 1():S19-28. PubMed ID: 8834928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?
    Gustafsson F; Segura J; Ruilope LM
    J Hypertens; 2010 Aug; 28(8):1595-8. PubMed ID: 20613629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of increased dose of diuretics on symptoms, weight, 6-minute walk distance, and echocardiographic measurements of left ventricular systolic and diastolic function in 51 patients with symptomatic heart failure caused by reduced left ventricular ejection fraction treated with beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
    Kumar A; Aronow WS; Vadnerkar A; Sivan K; Mittal S
    Am J Ther; 2009; 16(1):5-7. PubMed ID: 19142162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of angiotensin converting enzyme inhibitors on remodeling in clinical trials.
    Greenberg BH
    J Card Fail; 2002 Dec; 8(6 Suppl):S486-90. PubMed ID: 12555162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
    Verdecchia P; Angeli F; Cavallini C; Gattobigio R; Gentile G; Staessen JA; Reboldi G
    Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
    Böhm M; Pogue J; Kindermann I; Pöss J; Koon T; Yusuf S
    Eur J Heart Fail; 2014 Mar; 16(3):325-33. PubMed ID: 24464788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beta blockers in systolic heart failure.
    Jackowski L; Azam R
    Aust Fam Physician; 2008 Mar; 37(3):137-9. PubMed ID: 18345362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and pharmacologic management of chronic heart failure associated with left ventricular systolic dysfunction.
    Parra D; Marshall R; Soisson K
    Lippincotts Prim Care Pract; 1999; 3(3):316-32. PubMed ID: 10711133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Need and prospects for prevention of cardiac failure.
    Kannel WB
    Eur J Clin Pharmacol; 1996; 49 Suppl 1():S3-9. PubMed ID: 8834926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prevention of heart failure].
    Logeart D; Guiti C; Ennezat PV; Cohen-Solal A
    Arch Mal Coeur Vaiss; 1998 Nov; 91(11):1333-41. PubMed ID: 9864601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of heart failure with preserved systolic function.
    de Groote P; Herpin D; Diévart F; Hanon O; Trochu JN; Artigou JY; Galinier M; Habib G; Juillière Y; Neuder Y; Roudaut R; Komajda M
    Arch Cardiovasc Dis; 2008 May; 101(5):361-72. PubMed ID: 18656095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.